Thus, the beneficial effects on survival in breast cancer reported with aromatase inhibitors and the CDK4/6 inhibitors palbociclib and ribociclib is likely to also be mediated by their respective immune effects. The gene discussed is CYP19A1; the disease is breast cancer.